BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.950
-0.100 (-4.88%)
Apr 16, 2025, 10:26 AM EDT - Market open
BioCardia Employees
As of December 31, 2024, BioCardia had 20 total employees, including 16 full-time and 4 part-time employees. The number of employees did not change compared to the previous year.
Employees
20
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$2,900
Profits / Employee
-$397,300
Market Cap
9.13M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 316,000 |
Thermo Fisher Scientific | 125,000 |
Medtronic | 95,000 |
AstraZeneca | 92,900 |
Sanofi | 82,878 |
Novartis AG | 75,883 |
Becton, Dickinson and Company | 73,000 |
GSK plc | 68,629 |
BCDA News
- 5 days ago - BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - GlobeNewsWire
- 15 days ago - BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - GlobeNewsWire
- 20 days ago - BioCardia Reports 2024 Business Highlights and Financial Results - GlobeNewsWire
- 26 days ago - BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - GlobeNewsWire
- 5 weeks ago - BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - GlobeNewsWire
- 6 weeks ago - BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 2 months ago - BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - GlobeNewsWire